GLOH: Giving a Low Carbohydrate Diet to Overcome Hypertension

Sponsor
Baylor Research Institute (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04230928
Collaborator
(none)
61
1
2
27.8
2.2

Study Details

Study Description

Brief Summary

This study will test the preliminary efficacy of adding a very low carbohydrate dietary intervention to the evidence-based DPP-GLB on blood pressure reductions for lower-income AA men and women in a community-based clinic.

Condition or Disease Intervention/Treatment Phase
  • Other: Very low carbohydrate diet
  • Other: Standard DPP-GLB diet
  • Behavioral: Standard DPP-GLB program modules
N/A

Detailed Description

This study will evaluate the effects of consuming a very low carbohydrate (VLC) diet in a sustainable community care setting, in addition to routine medical care, to African American (AA) with pre-hypertension, hypertension (stage 1-3), or cardiovascular disease risk factors. This study will also secondarily assess the feasibility of following a VLC diet in a low-income, AA population.

Study Design

Study Type:
Interventional
Actual Enrollment :
61 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective randomized 2-group studyProspective randomized 2-group study
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Pilot Study Comparing Dietary Approaches to Decrease Hypertension in a Lower Income, African American Population at Risk for Cardiovascular Disease
Actual Study Start Date :
Mar 5, 2020
Actual Primary Completion Date :
Nov 18, 2021
Anticipated Study Completion Date :
Jun 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Standard GLB Control

Individuals will receive the standard Diabetes Prevention Program-Group Lifestyle Balance (GLB) program as outlined by the American Diabetes Association. This program will be taught at the Baylor Scott & White Health and Wellness Center by trained research staff.

Other: Standard DPP-GLB diet
Participants will learn to follow a very low fat, calorie-restricted diet and track fat grams and caloric intake in standard GLB modules 2,3,5, & 10

Behavioral: Standard DPP-GLB program modules
Participants will learn standard DPP-GLB modules for other lifestyle modifications for stress, physical activity, etc. in sessions 1,4,6-9, 11-22

Experimental: VLC-GLB Intervention

Individuals will receive a version of the DPP-GLB program in which 4 of the 12 modules will teach a very low carbohydrate diet instead of the standard. All other components of the DPP-GLB will follow the standard. This program will be taught at the Baylor Scott & White Health and Wellness Center by trained research staff.

Other: Very low carbohydrate diet
Participants will learn to follow a very low carbohydrate diet in modified versions of GLB modules 2,3,5 & 10. Participants will learn to track carbohydrate intake

Behavioral: Standard DPP-GLB program modules
Participants will learn standard DPP-GLB modules for other lifestyle modifications for stress, physical activity, etc. in sessions 1,4,6-9, 11-22

Outcome Measures

Primary Outcome Measures

  1. Changes in Systolic blood pressure [Baseline; 12 weeks; 10 months]

    Measure changes in both systolic and diastolic blood pressure using digital sphygmomanometer; NOTE: Only Systolic BP is primary outcome, diastolic change will be a secondary outcome measure

  2. Dietary changes in carbohydrate intake [Baseline; 12 weeks; 10 months]

    Assess changes in diet using ASA24 online dietary recall

Secondary Outcome Measures

  1. Changes in Fasting blood glucose [Baseline; 12 weeks; 10 months]

    Finger stick measure of blood glucose levels collected after 8-12 hours fasting

  2. Changes in Hemoglobin A1C [Baseline; 12 weeks; 10 months]

    Finger stick measure of hemoglobin A1C collected after 8-12 hours fasting

  3. Changes in Cholesterol and lipoproteins [Baseline; 12 weeks; 10 months]

    Finger stick measure of blood levels of total cholesterol, HDL, LDL, and triglycerides collected after 8-12 hours fasting

  4. Changes in % Body weight [Baseline; 12 weeks; 10 months]

    Change in weight measured in lbs. with digital scale; % change calculated

  5. Changes in Body mass index (BMI) [Baseline; 12 weeks; 10 months]

    Change in calculated BMI based upon height (in.) with stadiometer & weight (lbs.) with digital scale

  6. Dietary changes in fat intake [Baseline; 12 weeks; 10 months]

    Assess changes in diet using ASA24 online dietary recall

  7. Dietary changes in caloric intake [Baseline; 12 weeks; 10 months]

    Assess changes in diet using ASA24 online dietary recall

  8. Changes in Diastolic blood pressure [Baseline; 12 weeks; 10 months]

    Measure changes in both systolic and diastolic blood pressure using digital sphygmomanometer; NOTE: Only Systolic BP is primary outcome, diastolic change will be a secondary outcome measure

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 74 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
    1. men and women aged ≥ 18 years
    1. willingness to participate in a 10-month study
    1. systolic blood pressure > 120 mm/Hg +/- diastolic blood pressure > 80 mm/Hg
    1. African American race
Exclusion Criteria:
    1. diagnosed congestive heart failure
    1. Hypertension stage 4 or higher (e.g., SBP >180 mm/Hg; DBP > 110 mm/Hg)
    1. received or needing more than 3 anti-hypertensive medications
    1. pregnant or planning to become pregnant
    1. receiving or needing a heart transplant
    1. Using injected long or short-acting insulin for diabetes treatment
    1. not African American race
    1. unable to speak and read English with fluency

Contacts and Locations

Locations

Site City State Country Postal Code
1 Baylor Research Institute Dallas Texas United States 75210

Sponsors and Collaborators

  • Baylor Research Institute

Investigators

  • Principal Investigator: Aisha H Montgomery, MD, MPH, Baylor Scott and White Health

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Baylor Research Institute
ClinicalTrials.gov Identifier:
NCT04230928
Other Study ID Numbers:
  • 019-268
First Posted:
Jan 18, 2020
Last Update Posted:
Dec 17, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Baylor Research Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 17, 2021